Venous thromboembolism presenting as lower limb deep vein thrombosis in a patient with active cancer — specifically where the cancer has no gastrointestinal or genitourinary involvement.
Current evidence supports a class of oral anticoagulants as the preferred first-line option in this setting, recommended over older injectable and oral alternatives. Selection among the specific agents within this class and the full clinical algorithm are detailed in the complete protocol.
DOI: 10.3949/ccjm.91a.22090
In patients with cancer-associated VTE, oral factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) are recommended over LMWH or vitamin K antagonists because of the oral administration of DOACs and their safety and efficacy without the need for laboratory monitoring.
View source ↗